🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareFDA compounding enforcement update — June 2026 guidance document Page 8

FDA compounding enforcement update — June 2026 guidance document

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 336 replies 53,782 viewsPage 8 of 20
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Mar 8, 2024 at 1:17 AM#36
HPLC_Greg said:
Vendor communication red flags for compounded supply: Won't provide COA before purchase — walk away Claims "100% pure" without analytical data —…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

Last edited: Mar 8, 2024 at 7:17 AM
49 24Dr.NateNeph, PharmD_Rodriguez, julia.endo and 46 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Mar 8, 2024 at 10:27 AM#37
HPLC_Greg said:
Vendor communication red flags for compounded supply: Won't provide COA before purchase — walk away Claims "100% pure" without analytical data —…

That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.

Last edited: Mar 8, 2024 at 4:27 PM
48 23alex_tucson, kevin_tulsa, Dr.PainCLE and 45 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Mar 8, 2024 at 7:37 PM#38
HPLC_Greg said:
Vendor communication red flags for compounded supply: Won't provide COA before purchase — walk away Claims "100% pure" without analytical data —…

Thank you for spelling out the reasoning rather than just the conclusion.

47 22Dr.NateNeph, PharmD_Rodriguez, julia.endo and 44 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Mar 9, 2024 at 4:47 AM#39

Adding the clinical framing, because it changes how the question reads. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

46 21jason_sac26, chris_chi24, tampaLisa73 and 43 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Mar 9, 2024 at 1:58 PM#40
julia.endo said:
The version of this that has an answer is narrower than the version being asked.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

Last edited: Mar 9, 2024 at 2:58 PM
24 24lucas_SP_BR, lisa_labSD, adam_van and 21 others
Reply Quote Save Share Report
167891020

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register